Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
Date:7/30/2008

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the second quarter ended June 30, 2008.

"The first half of 2008 has been a remarkably productive time at Anadys," said Steve Worland, Ph.D., President and CEO. "Through the focused efforts of our employees, we have initiated dosing in three clinical programs in six months. For hepatitis C, we commenced dosing in our Phase I clinical trial of ANA598 during the second quarter, and are happy to announce today that we have now commenced dosing in our Phase I clinical trial of ANA773 for HCV. We also continue to enroll patients in our ongoing clinical trial of ANA773 for oncology. We are proud of our progress to date and look forward to achieving additional clinical milestones in the coming months."

Financial Results

As of June 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $42.1 million.

During the second quarter of 2008 the Company had no revenue, compared to $1.3 million for the same quarter of 2007. The revenue in the second quarter of 2007 was primarily derived from the amortization of an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $5.5 million for the second quarter of 2008, compared to $7.0 million for the second quarter of 2007. The $1.5 million decrease primarily resulted from cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs. The
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
6. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
7. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
8. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
9. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... A new selection of laboratory ... is designed to meet the dynamic needs of ... new Cole-Parmer® MS-3400 Centrifuges are clinical ... They ensure a powerful and complete separation of ... standard four-place swinging buckets hold 50-mL tubes. With ...
(Date:5/16/2013)... 2013 Kitware , a ... announces new Phase II SBIR funding from the ... of an open-source, high performance computing (HPC) simulation ... enables researchers to select only the toolkits and ... computation, or analysis tasks. , Manufacturers increasingly ...
(Date:5/16/2013)... -- The registration deadline has been extended until May 22 ... Conference, the premier conference for bioscience financial officers. The ... San Diego Bayfront. "We are putting ... to make sure as many people as possible have ... , Chief Financial Officer of Mast Therapeutics, Inc. ...
(Date:5/16/2013)... 2013 As the weather warms, women everywhere ... Spring looks. While most make a statement with fashion, many ... find the warmer weather mixes makeup and sweat to produce, ... onset of acne during warmer months, Adult Acne treatment ... users the best ways to deter breakouts. , Recently, ...
Breaking Biology Technology:Cole-Parmer Offers Enhanced Selection of Centrifuges 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2
... Calif., May 21 AutoGenomics, a leader in developing ... team comprised of the Canada Research Chair in Medical ... new viruses and antiviral resistance, Professor Guy Boivin has ... for the presence of the new Flu A - ...
... giveaways show state,s growing germ-fighting focus ATLANTA, ... contingent to this week,s Biotechnology Industry Organization (BIO) ... they press the flesh with thousands of conference ... is distributing hundreds of containers of hand sanitizers ...
... (the "Company") (Nasdaq: KERX ) announced today the ... Company. It is also anticipated that Ron Bentsur will join ... the board on June 16, 2009.Michael P. Tarnok, Interim Chairman ... the Board, I want to welcome Ron Bentsur to Keryx. ...
Cached Biology Technology:AutoGenomics New RVP Assay Addresses Current Challenge to Detect Flu A - Swine H1N1 2BIO Visitors Bring Viral Preparedness to Atlanta 2BIO Visitors Bring Viral Preparedness to Atlanta 3Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer 2Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer 3Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer 4
(Date:5/15/2013)... behavioral effects on diverse organisms often play large ... a theory proposed in the June issue of ... Ryan P. Ferrer of Seattle Pacific University and ... at Los Angeles, liken such molecules to keystone ... but exert a controlling influence, through predation or ...
(Date:5/15/2013)... of reducing greenhouse gas (GHG) emissions to 17 per ... federal and provincial governments, led by the Prime Minister ... of the total GHG reduction will be provided by ... School of the Environment. Their report is being ... parties and other participants in the climate policy dialogue. ...
(Date:5/15/2013)... strategic plan, " Forging the Future A Ten-Year ... Genome Institute (DOE JGI) has positioned itself to provide ... so that they can address pressing energy and environmental ... in this process is the launch of the ... of the ETOP is to develop and support selected ...
Breaking Biology News(10 mins):Natural 'keystone molecules' punch over their weight in ecosystems 2Canada must addess real climate-change challenge 2Canada must addess real climate-change challenge 3The DOE Joint Genome Institute expands capabilities via new partnerships 2The DOE Joint Genome Institute expands capabilities via new partnerships 3
... virus has a problem: it is a giant among viruses ... cell and reproduce. Professor Ari Helenius and Postdoc Jason Mercer ... this strategy is. In the process, they stumbled upon new ... In order to infiltrate a cell, the vaccinia virus ...
... a broad range of genetic tests. Paternity tests ... future baldness. With ongoing genetic discoveries and ... ever before and along with greater availability has ... How can consumers make informed decisions about genetic ...
... issues is the development of techniques that increase the ... 24, 2008 in the journal Vaccine, a Massachusettss biotechnology ... for anti-viral vaccination. This technology consists of two major ... two forms. One is easily processed within the organisms ...
Cached Biology News:A step forward in virology 2A step forward in virology 3American College of Medical Genetics makes genetic testing recommendations in new policy statement 2New technology for boosting vaccine efficiency 2New technology for boosting vaccine efficiency 3
Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
... UbcH7 interacts with the HECT ... RING domain. Evidence suggests that ... both the degradation of non-""N-end ... certain N-a -acetylated proteins as ...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Reacts with methylated DNA from plants and vertebrates...
Biology Products: